Advertisement

Metabolic Brain Disease

, Volume 34, Issue 5, pp 1467–1472 | Cite as

The effect of hyperglycinemic treatment in captive-bred Vervet monkeys (Chlorocebus aethiops)

  • Zandisiwe E. MagwebuEmail author
  • Mikateko Mazinu
  • Sahar Abdul-Rasool
  • Chesa G. Chauke
Original Article
  • 34 Downloads

Abstract

Nonketotic hyperglycinemia (NKH) is a neuro-metabolic disorder caused by a deficiency in the glycine cleavage system (GCS) and glycine transporter 1 (GlyT1). A case of atypical late onset of NKH has been reported in a colony of captive-bred Vervet monkeys. The purpose of this study was to evaluate the effect of sodium benzoate and dextromethorphan in reducing glycine levels in hyperglycinemic monkeys. Twelve captive-bred Vervet monkeys were assigned into three groups consisting of four animals (control, valproate induced and cataract with spontaneous hyperglycinemia). Valproate was used to elevate glycine levels and the induced group was then treated with sodium benzoate and dextromethorphan together with group three to normalise glycine levels in cerebrospinal fluid (CSF) and plasma. Valproate induction elicited changes in phosphate, alkaline phosphatase and platelet count, however, no significant changes in the glycine levels were observed, and this might be due to the individual variability within the group. The treatment intervention was only obtained in the spontaneous group whereby the glycine levels were normalised in CSF and plasma. Therefore, it can be concluded that sodium benzoate and dextromethorphan treatment was effective and beneficial to the hyperglycinemic group.

Keywords

Dextromethorphan Glycine Sodium benzoate Spontaneous hyperglycinemia Valproate and Vervet monkey 

Notes

Acknowledgements

The authors express their gratitude to Joritha van Heerden, Timothy Collop and Abraham Davids for their excellent expertise in handling Vervet monkeys. The South African Medical Research Council/ Primate Unit and Delft Animal Centre for financial support.

Funding

The authors did not receive any research grant for this study, however, financial support was provided by the Primate Unit and Delft Animal Centre (PUDAC) of the South African Medical Research Council.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This study was approved by the SAMRC Ethics Committee for Research on Animals (ECRA) (Ref.08/13). All procedure performed in study involving animals were in accordance with the ethical standards of the South African National Standard for the Care and Use of Animals for Scientific Purposes (South African Bureau of Standards, SANS 10386, 2008).

References

  1. Aghebati T, Foroughipour M, Azarpazhooh MR, Mokhber N, Khayat MH, Vahdati N, Mohammadpour AH (2012) Relationship between patient demographic characteristics, Valproic acid dosage and clearance in adult Iranian patients. Iran J Basic Med Sci 15:702Google Scholar
  2. Ahmed SN, Siddiqi ZA (2006) Antiepileptic drugs and liver disease. Seizure 15:156–164CrossRefGoogle Scholar
  3. Applegarth DA, Toone JR (2006) Glycine encephalopathy (nonketotic hyperglycinemia): comments and speculations. Am J Med Genet A 140:186–188CrossRefGoogle Scholar
  4. Arnold G, Griebel M, Valentine J, Koroma D, Kearns G (1997) Dextromethorphan in nonketotic hyperglycinaemia: metabolic variation confounds the dose-response relationship. J Inherit Metab Dis 20:28–38CrossRefGoogle Scholar
  5. Bhamkar RP, Colaco P (2007) Neonatal nonketotic hyperglycinemia. Indian J Pediatr 74:1124–1126CrossRefGoogle Scholar
  6. Boneh A, Korman SH, Sato K, Kanno J, Matsubara Y, Lerer I, Ben-Neriah Z, Kure S (2005) A single nucleotide substitution that abolishes the initiator methionine codon of the GLDC gene is prevalent among patients with glycine encephalopathy in Jerusalem. J Hum Genet 50:230–234CrossRefGoogle Scholar
  7. Chatzistefanidis D, Georgiou I, Kyritsis AP, Markoula S (2012) Functional impact and prevalence of polymorphisms involved in the hepatic glucuronidation of valproic acid. Pharmacogenomics 13:1055–1071CrossRefGoogle Scholar
  8. Chauke CG, Magwebu ZE, Sharma JR, Arieff Z, Seier JV (2016) Mutation analysis of GLDC, AMT and GCSH in cataract captive-bred vervet monkeys (Chlorocebus aethiops). J Med Primatol 45:189–194CrossRefGoogle Scholar
  9. Churchill A, Graw J (2011) Clinical and experimental advances in congenital and paediatric cataracts. Phil Trans R Soc B 366:1234–1249CrossRefGoogle Scholar
  10. De Villiers C, Seier JV, Dhansay MA (2001) Probable genetic origin for a large number of cataracts among captive-bred vervet monkeys (Chlorocebus aethiops). Am J Primatol 55:43–48CrossRefGoogle Scholar
  11. Delgado MR, Riela AR, Mills J, Browne R, Roach ES (1994) Thrombocytopenia secondary to high valproate levels in children with epilepsy. J Child Neurol 9:311–314CrossRefGoogle Scholar
  12. Dinopoulos A, Matsubara Y, Kure S (2005) Atypical variants of nonketotic hyperglycinemia. Mol Genet Metab 86:61–69CrossRefGoogle Scholar
  13. Espandiari P, Zhang J, Schnackenberg LK, Miller TJ, Knapton A, Herman EH, Beger RD, Hanig JP (2008) Age-related differences in susceptibility to toxic effects of valproic acid in rats. J Appl Toxicol 28:628–637CrossRefGoogle Scholar
  14. Gregus Z, Fekete T, Halászi É, Gyurasics Á, Klaassen CD (1998) Effects of fibrates on the glycine conjugation of benzoic acid in rats. Drug Metab Dispos 26:1082–1088Google Scholar
  15. Guo Y, Hu C, He X, Qiu F, Zhao L (2012) Effects of UGT1A6, UGT2B7, and CYP2C9 genotypes on plasma concentrations of valproic acid in Chinese children with epilepsy. Drug Metab Pharmacokinet 27:536–542CrossRefGoogle Scholar
  16. Hamosh A, Mcdonald JW, Valle D, Francomano CA, Niedermeyer E, Johnston MV (1992) Dextromethorphan and high-dose benzoate therapy for nonketotic hyperglycinemia in an infant. J Pediatr 121:131–135CrossRefGoogle Scholar
  17. Hamosh A, Maher JF, Bellus GA, Rasmussen SA, Johnston MV (1998) Long-term use of high-dose benzoate and dextromethorphan for the treatment of nonketotic hyperglycinemia. J Pediatr 132:709–713CrossRefGoogle Scholar
  18. Hauser E, Seidl R, Freilinger M, Male C, Herkner K (1996) Hematologic manifestations and impaired liver synthetic function during valproate monotherapy. Brain Dev 18:105–109CrossRefGoogle Scholar
  19. Hejtmancik J. F. Congenital cataracts and their molecular genetics. Semin Cell Dev Biol, 2008. Elsevier, 134–149Google Scholar
  20. Hennermann JB (2006) Clinical variability in glycine encephalopathy. Future Neurol 1:621.630CrossRefGoogle Scholar
  21. Hennermann JB, Berger JM, Grieben U, Scharer G, Van Hove JL (2012) Prediction of long-term outcome in glycine encephalopathy: a clinical survey. J Inherit Metab Dis 35:253–261CrossRefGoogle Scholar
  22. Hoover-Fong JE, Shah S, Van Hove JL, Applegarth D, Toone J, Hamosh A (2004) Natural history of nonketotic hyperglycinemia in 65 patients. Neurology 63:1847–1853CrossRefGoogle Scholar
  23. Hung C-C, Ho J-L, Chang W-L, Tai JJ, Hsieh T-J, Hsieh Y-W, Liou H-H (2011) Association of genetic variants in six candidate genes with valproic acid therapy optimization. Pharmacogenomics 12:1107–1117CrossRefGoogle Scholar
  24. Hussain S, Mordekar S, Prasad M (2013) The calm before the storm?: late onset Glycine encephalopathy masquerading as gastro-oesophageal reflux. J Neurodev Disord 2013Google Scholar
  25. Karaoglu A, Vurucu S, Okutan V, Kurekci AE, Caycý T, Atay A, Akin R, Gokcay E (2009) Valporic acid: is it safe to use in epileptic pediatric patient? Pak J Med Sci July–September 25:539–544Google Scholar
  26. Koenig SA, Buesing D, Longin E, Oehring R, Häussermann P, Kluger G, Lindmayer F, Hanusch R, Degen I, Kuhn H (2006) Valproic acid–induced Hepatopathy: nine new fatalities in Germany from 1994 to 2003. Epilepsia 47:2027–2031CrossRefGoogle Scholar
  27. Kojima-Ishii K, Kure S, Ichinohe A, Shinka T, Narisawa A, Komatsuzaki S, Kanno J, Kamada F, Aoki Y, Yokoyama H (2008) Model mice for mild-form glycine encephalopathy: behavioral and biochemical characterizations and efficacy of antagonists for the glycine binding site of N-methyl D-aspartate receptor. Pediatr Res 64:228–233CrossRefGoogle Scholar
  28. Kure S, Kato K, Dinopoulos A, Gail C, Degrauw TJ, Christodoulou J, Bzduch V, Kalmanchey R, Fekete G, Trojovsky A (2006) Comprehensive mutation analysis of GLDC, AMT, and GCSH in nonketotic hyperglycinemia. Hum Mutat 27:343–352CrossRefGoogle Scholar
  29. Madu AE, Oliver L (2013) Non-ketotic hyperglycinaemia: case report and review of medical literature. J Matern Fetal Neonatal Med 26:537–539CrossRefGoogle Scholar
  30. Magwebu ZE, Abdul-Rasool S, Seier JV, Chauke CG (2018) Autosomal recessive congenital cataract in captive-bred vervet monkeys (Chlorocebus aethiops). J Med Primatol 47:93–100CrossRefGoogle Scholar
  31. Nasreddine W, Beydoun A (2008) Valproate-induced thrombocytopenia: a prospective monotherapy study. Epilepsia 49:438–445CrossRefGoogle Scholar
  32. Neuberger JM, Schweitzer S, Rolland MO, Burghard R (2000) Effect of sodium benzoate in the treatment of atypical nonketotic hyperglycinaemia. J Inherit Metab Dis 23:22–26CrossRefGoogle Scholar
  33. Ramirez N, Flynn JM, Casalduc F, Rodriguez S, Cornier AS, Carlo S (2012) Musculoskeletal manifestations of neonatal nonketotic hyperglycinemia. J Child Orthop 6:199–203CrossRefGoogle Scholar
  34. Randak C, Roschinger W, Rolinski B, Hadorn HB, Applegarth DA, Roscher AA (2000) Three siblings with nonketotic hyperglycinaemia, mildly elevated plasma homocysteine concentrations and moderate methylmalonic aciduria. J Inherit Metab Dis 23:520–522CrossRefGoogle Scholar
  35. Roy D, Al-Asmari A, Ghazal Y, Al-Oqiel S (2003) Nonketotic hyperglycinemia in Suleimaniah Children's hospital, Riyadh, Saudi Arabia. Ann Saudi Med 24:378–381CrossRefGoogle Scholar
  36. Star K., Edwards I. R.. Choonara I. (2014). Valproic acid and fatalities in children: a review of individual case safety reports in VigiBaseGoogle Scholar
  37. Van Hove JL, Vande Kerckhove K, Hennermann JB, Mahieu V, Declercq P, Mertens S, De Becker M, Kishnani PS, Jaeken J (2005) Benzoate treatment and the glycine index in nonketotic hyperglycinaemia. J Inherit Metab Dis 28:651–663CrossRefGoogle Scholar
  38. Viljoen J, Bergh JJ, Mienie LJ, Kotze HF, Terre’blanche G (2012) Paracetamol prevents hyperglycinemia in vervet monkeys treated with valproate. Metab Brain Dis 27:327–335CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Primate Unit and Delft Animal CentreSouth African Medical Research CouncilTygerbergSouth Africa
  2. 2.Medical Bioscience DepartmentUniversity of the Western CapeBelvilleSouth Africa

Personalised recommendations